Simcere Pharmaceutical signs exclusive global licensing deal for SIM0660
Simcere Pharmaceutical Group entered an exclusive global licensing agreement with Roche for SIM0660, according to TradingView News.
Story updates
10:26:41 AM UTC
SquawkNews
Chinese drugmaker Simcere Pharmaceutical signed a licensing agreement with Roche on Monday, granting the Swiss pharmaceutical company exclusive global rights to develop, manufacture and commercialise SIM0660, an antibody targeting B-cell cancers.As per deal terms, Simcere is eligible to receive $75…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.